An observational study in Breast Cancer, sponsored by Hunan Cancer Hospital. Enrolling by invitation at 1 site in China. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Hunan Cancer Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Breast Neoplasms by Hunan Cancer Hospital — 10 open to participants now, 10 under way, none of them phase 3. Breast Neoplasms · Hunan Cancer Hospital.
Among the 15 studies in Breast Neoplasms by Hunan Cancer Hospital, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2024, is one of 10 observational ones, and was the 15th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →10 of the 15 studies in Breast Neoplasms by Hunan Cancer Hospital are open now, in 1 country. Recruiting first, the newest first:
Hunan Cancer Hospital · Sites in China
Ages 45–74 · Healthy volunteers
Hunan Cancer Hospital · Sites in China
Ages 18–75 · Women only
Hunan Cancer Hospital · Sites in China
Ages 18–75 · Women only
Hunan Cancer Hospital · Sites in China
Ages 18+
Hunan Cancer Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 86 across the 5 interventional studies, 200 across the 10 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hunan Cancer Hospital is the lead sponsor of 56 studies on the registry; 29 are open to participants now.
2 of the studies in Breast Neoplasms by Hunan Cancer Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07163481Hunan Cancer HospitalA Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors | 2026-12 |
| NCT07676383Hunan Cancer HospitalPrecision Navigation to Improve Community Cancer Screening Participation | 2027-03-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Breast Neoplasms by Hunan Cancer Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study uses FES PET/CT imaging to evaluate estrogen receptor-positive breast cancer. FES PET/CT is a type of imaging that can show whether breast cancer cells have estrogen receptors. The purpose of this study is to see how well FES PET/CT can help doctors: (1) diagnose ER-positive breast cancer, (2) plan the best treatment, and (3) check how well treatment is working. Participants will undergo FES PET/CT scans as part of their regular cancer care or study procedures. The results may help improve how doctors use imaging to guide treatment decisions for patients with ER-positive breast cancer.
Estrogen receptor (ER) status is a critical determinant of treatment strategy in breast cancer. While 18F-FDG PET/CT is widely used for metabolic assessment, it cannot directly visualize ER expression. 18F-FES is a radiolabeled estrogen analog that binds specifically to ER, enabling non-invasive visualization and quantification of ER expression in vivo. The combined use of 18F-FDG and 18F-FES PET/CT may provide complementary metabolic and receptor information for diagnosis, treatment planning, and therapeutic response assessment in ER-positive breast cancer.This study aims to evaluate the clinical utility of FES PET/CT in three domains: (1) diagnosis and characterization of ER-positive breast cancer lesions, (2) informing treatment planning by assessing ER expression heterogeneity, and (3) monitoring treatment response through quantitative changes in FES uptake.
patients with suspected or new diagnosed or previously treated ER-positive breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Performance
Diagnostic accuracy, The sensitivity, specificity and accuracy of 18F-FES PET/CT were calculated.
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Dec 2028, 55 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hunan Cancer Hospital